Forte Biosciences Faces Critical Test as Losses Expected to Widen Sharply

Forte Biosciences Inc (FBRX) reports fourth-quarter 2025 earnings on March 27, with analysts bracing for a significant deterioration in losses. The biotech faces a pivotal moment as the Street weighs clinical progress against mounting cash burn, with the consensus pointing to the company's largest quarterly loss in recent history.

Part 1: Earnings Preview

Forte Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for dermatological and autoimmune diseases. The company's pipeline centers on FB-401, its lead investigational product candidate targeting atopic dermatitis and other inflammatory skin conditions.

Analysts expect Forte to report a loss of $1.42 per share for the fourth quarter of 2025, representing a dramatic deterioration from the $0.99 loss reported in the third quarter. Compared to the same quarter last year, the expected loss reflects a 100.14% increase in losses year-over-year, signaling intensifying cash consumption as the company advances its clinical programs.

Three key themes define this earnings story:

Clinical Development Trajectory: Investors will scrutinize updates on FB-401's clinical trial progress and any data readouts that could validate the company's therapeutic approach. The pace and success of patient enrollment, along with any preliminary efficacy signals, will be critical to justifying the elevated burn rate.

Cash Runway and Financing Strategy: With losses widening substantially, the company's cash position and plans for extending its operational runway take center stage. Any commentary on strategic partnerships, potential licensing deals, or capital raising plans will heavily influence investor sentiment.

Regulatory Pathway Clarity: The market seeks greater visibility into Forte's regulatory strategy and timeline for potential approval milestones. Clear articulation of the path forward and any FDA feedback could provide confidence despite near-term losses.

Analyst commentary ahead of the release reflects cautious optimism tempered by financial realities. The wide range in estimates—from a low of $1.78 loss to a high of $1.06 loss—underscores significant uncertainty around the company's quarterly performance and spending patterns.

Part 2: Historical Earnings Performance

Forte Biosciences has demonstrated an inconsistent earnings track record over recent quarters. In Q1 2025, the company reported a $1.37 loss per share against an estimate of $0.89, missing by 53.93% in a significant disappointment. The company rebounded in Q2 2025, posting a $0.96 loss versus the $1.21 expected, beating estimates by 20.66%. Most recently in Q3 2025, FBRX reported a $0.99 loss compared to the $1.04 consensus, delivering a modest 4.81% beat.

The pattern reveals improving execution over the past two quarters after the substantial Q1 miss, though losses have remained elevated throughout. The company has beaten or met estimates in two of the last three reported quarters, suggesting management may be gaining better control over spending and guidance. However, the sharp widening of expected losses for Q4—to $1.42 from $0.99 last quarter—indicates either accelerated investment in clinical programs or one-time expenses that could disrupt the recent trend of modest beats.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Forte Biosciences has not specified an earnings release time, though historical patterns suggest reporting may occur outside regular trading hours.

Historical price action around earnings shows moderate volatility with an average absolute Day 0 move of 3.56% and Day +1 move of 6.02%. The stock has exhibited mixed directional bias, with three positive Day 0 reactions and three negative ones over the past seven reports. Notably, the most dramatic move came in August 2024, when shares plunged 20.51% the day after earnings with an intraday range of 37.72%—highlighting the potential for outsized reactions when results significantly disappoint. More recent quarters have shown more contained moves, with the last three reports producing Day 0 moves between 1.59% and 3.03%. The average Day 1 range of 12.43% suggests substantial intraday volatility as investors digest results and management commentary.

Part 2.2: Options Market Expected Move

The options market is pricing a 14.73% expected move (±$4.00) by April 17 expiration, significantly higher than the stock's average historical Day 0 move of 3.56% and even exceeding the average Day +1 move of 6.02%. This elevated implied volatility suggests options traders are anticipating a more dramatic reaction than typical, possibly reflecting heightened uncertainty around clinical updates or financing announcements that could accompany the earnings release.

Part 3: What Analysts Are Saying

Analysts maintain a strongly bullish stance on Forte Biosciences, with the consensus rating at 4.71 out of 5.0—firmly in Strong Buy territory. The rating breakdown shows 6 Strong Buy recommendations, 0 Moderate Buys, 1 Hold, and no Sell ratings among the 7 analysts covering the stock. This overwhelmingly positive view has remained unchanged over the past month, indicating stable conviction despite the expected widening of losses.

The average price target of $63.75 implies substantial 136% upside from the current price of $27.01, with individual targets ranging from a low of $54.00 to a high of $75.00. The tight clustering of targets—with even the most conservative estimate suggesting 100% upside—reflects broad agreement that the stock is significantly undervalued relative to its clinical potential. This consensus suggests analysts are looking through near-term losses and focusing on the long-term value creation opportunity if FB-401 succeeds in clinical development.

Part 4: Technical Picture

The Barchart Technical Opinion currently registers a 40% Buy signal, down from 72% Buy a month ago, indicating deteriorating technical momentum heading into the earnings release. The signal has held steady at 40% Buy over the past week, suggesting the recent weakness has stabilized but not reversed.

Timeframe Analysis:

• Short-term (Hold): Neutral signal indicates near-term momentum has stalled, with the stock lacking clear directional conviction
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend remains cautiously constructive despite recent softness
• Long-term (100% Buy): Strong buy signal reflects solid upward trajectory over extended timeframes, supported by the stock's position well above its 200-day moving average

Trend Characteristics: The technical environment shows Average strength with a Weakening direction, suggesting the stock is losing momentum as it approaches earnings despite maintaining a generally positive longer-term structure.

The stock trades at $27.01, positioned above its 5-day ($25.64), 10-day ($25.83), 100-day ($25.05), and 200-day ($18.58) moving averages, but has slipped below both its 20-day ($27.56) and 50-day ($29.47) averages. This configuration—above long-term support but below intermediate-term resistance—suggests the stock is in a consolidation phase after a strong longer-term advance. The 200-day moving average at $18.58 provides significant support roughly 31% below current levels, while the 50-day at $29.47 represents near-term resistance just 9% higher.

Key technical levels to watch include the 50-day moving average at $29.47 as overhead resistance and the 100-day at $25.05 as nearby support. The stock's position in the middle of this range, combined with weakening momentum indicators, creates a neutral-to-cautious technical setup heading into earnings. A strong beat and positive clinical updates could propel shares back above the 50-day average and reignite the uptrend, while disappointment could test support at the 100-day moving average. The deteriorating short-term signal and weakening trend direction suggest the stock may be vulnerable to downside volatility if results fail to meet expectations.